Results 171 to 180 of about 1,296,096 (233)

The Therapeutic Paradox of Endocannabinoid Immunomodulation: Molecular Mechanisms and Strategic Frameworks. [PDF]

Int J Mol Sci
Love CR.
europepmc   +1 more source

Might modulation of the endocannabinoid system provide a potential dual therapeutic strategy for osteoporosis and depression? [PDF]

Gen Psychiatr
Wei P, Zhao P, Gu Z, Yang M, Karasik D, Cheung CL, Zheng H.   +6 more
europepmc   +1 more source

Selective CB₂ Agonist <i>JWH-133</i> Suppresses Viability and Migration-Related Responses in Prostate Cancer Cells. [PDF]

Pharmaceuticals (Basel)
Özcan SS, Yapar R, Değerli İ, Elmas L, Korkmaz M, Çakır M.   +5 more
europepmc   +1 more source

Multiple binding modes underlie <i>Cannabis sativa</i> cannabinoids recognition by peroxisome proliferator-activated receptor gamma. [PDF]

Front Bioinform
Alves NRC, Miranda J, Alvarez LD.
europepmc   +1 more source

Emerging roles of cannabinoid pathways in renal injury and repair. [PDF]

Front Pharmacol
Romero-Guevara R, Guzmán-Rodríguez S, Marichal-Cancino BA.   +2 more
europepmc   +1 more source

Dimethylindanoylindole Isomers Revealed Different Pharmacological Profiles at CB1 and CB2 Cannabinoid Receptors. [PDF]

ACS Bio Med Chem Au
Oh SJ, Guo R, Lucaj C, Gutierrez N, Ahmed KT, Williams AH, Zhan CG, Dudley GB, Yano H.   +8 more
europepmc   +1 more source

AB-MDMSBA-Not a Synthetic Cannabinoid Receptor Agonist. [PDF]

Pharmacol Res Perspect
Patel M, Ganeshan D, Horgan I, Partington H, Glass M.   +4 more
europepmc   +1 more source

Neuropharmacology of Cannabinoids: A Comprehensive Review of Preclinical and Clinical Evidence for Hemp-Derived Extracts and Active Compounds. [PDF]

Pharmaceuticals (Basel)
Odonkor CA, Karpe DA, Siddique MU, Abd-Elsayed A.   +3 more
europepmc   +1 more source

Tissue-specific roles of monoacylglycerol (MAG) in metabolic diseases. [PDF]

Immunometabolism (Cobham)
Park MY, Mooring A, Bruno J, Alemán JO.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biased agonism at the cannabinoid receptors – Evidence from synthetic cannabinoid receptor agonists

Cellular Signalling, 2021
The type 1 and type 2 cannabinoid receptors are G protein-coupled receptors implicated in a variety of physiological processes and diseases. Synthetic cannabinoid receptor agonists (SCRAs) were originally developed to explore the therapeutic benefits of cannabinoid receptor activation, although more recently, these compounds have been diverted to the ...
David Finlay, Michelle Glass, Mónica Patel   +2 more
exaly   +3 more sources